Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This study is comparing two maintenance (ongoing) treatments for women with hormone receptor-positive, HER2-negative metastatic breast cancer after completing initial chemotherapy: fulvestrant (a hormone-blocking injection) versus capecitabine (an oral chemotherapy pill), to find out which keeps the cancer at bay longer. **You may be eligible if:** - You are a woman aged 18–75 with advanced hormone receptor-positive, HER2-negative breast cancer - Your cancer did not progress (was stable, improved, or completely responded) after 4–8 cycles of first-line chemotherapy - You have not had more than one prior chemotherapy line for advanced disease **You may NOT be eligible if:** - Your cancer progressed during your initial chemotherapy - You have already received fulvestrant or other hormonal treatments for metastatic disease - You are pregnant or breastfeeding - You have significant organ dysfunction Talk to your doctor to see if this trial is right for you.